Bernhard Frank

Bernhard Frank

Auto-generated profile, based on publicly available information

Bernhard Frank

University of Liverpool Liverpool UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2008 in BMJ
Verified
Journal Article
Closed access
PDF file
BFB Frank
B Frank
MSM G Serpell
M G Serpell
JHJ Hughes
J Hughes
JMJ N S Matthews
J N S Matthews
DKD Kapur
D Kapur
Objective To compare the analgesic efficacy and side effects of the synthetic cannabinoid nabilone with those of the weak opioid dihydrocodeine for chronic neuropathic pain. Design Randomised, double blind, crossover trial of 14 weeks’ duration comparing dihydrocodeine and nabilone.Setting Outpatient units of three hospitals in the United Kingdom.Participants 96 patients with chronic neuropathic pain, aged 23-84 years. Main outcome measures The primary outcome was difference between nabilone and dihydrocodeine in pain, as measured by the mean visual analogue score computed over the last 2 weeks of each treatment period. Secondary outcomes were changes in mood, quality of life, sleep, and psychometric function. Side effects were measured by a questionnaire.Intervention Patients received a maximum daily dose of 240 mg dihydrocodeine or 2 mg nabilone at the end of each escalating treatment period of 6 weeks. Treatment periods were separated by a 2 week washout period.Results Mean baseline visual analogue score was 69.6 mm (range 29.4-95.2) on a 0-100 mm scale. 73 patients were included in the available case analysis and 64 patients in the per protocol analysis. The mean score was 6.0 mm longer for nabilone than for dihydrocodeine (95% confidence interval 1.4 to 10.5) in the available case analysis and 5.6 mm (10.3 to 0.8) in the per protocol analysis. Side effects were more frequent with nabilone.Conclusion Dihydrocodeine provided better pain relief than the synthetic cannabinoid nabilone and had slightly fewer side effects, although no major adverse events occurred for either drug. Trial registration Current Controlled Trials ISRCTN15330757.

3 October 2017 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
AGAndreas Goebel
Andreas Goebel
JBJatinder Bisla
Jatinder Bisla
RCRoy Carganillo
Roy Carganillo
BFBernhard Frank
Bernhard Frank
RGRima Gupta
Rima Gupta
GAGareth Ambler
Gareth Ambler
Two small trials suggest that low-dose intravenous immunoglobulin (IVIg) may improve the symptoms of complex regional pain syndrome (CRPS), a rare posttraumatic pain condition. To confirm the efficacy of low-dose IVIg compared with placebo in reducing pain during a 6-week period in adult patients who had CRPS from 1 to 5 years. 1:1 parallel, randomized, placebo-controlled, multicenter trial for 6 weeks, with an optional 6-week open extension. Patients were randomly assigned to 1 of 2 study groups between 27 August 2013 and 28 October 2015; the last patient completed follow-up on 21 March 2016. Patients, providers, researchers, and outcome assessors were blinded to treatment assignment. (ISRCTN42179756) 7 secondary and tertiary care pain management centers in the United Kingdom. 111 patients with moderate or severe CRPS of 1 to 5 years' duration. IVIg, 0.5 g/kg of body weight, or visually indistinguishable placebo of 0.1% albumin in saline on days 1 and 22 after randomization. The primary outcome was 24-hour average pain intensity, measured daily between days 6 and 42, on an 11-point (0- to 10-point) rating scale. Secondary outcomes were pain interference and quality of life. The primary analysis sample consisted of 108 eligible patients, 103 of whom had outcome data. Mean (average) pain scores were 6.9 points (SD, 1.5) for placebo and 7.2 points (SD, 1.3) for IVIg. The adjusted difference in means was 0.27 (95% CI, −0.25 to 0.80; P = 0.30), which excluded the prespecified, clinically important difference of −1.2. No statistically significant differences in secondary outcomes were found between the groups. In the open extension, 12 of the 67 patients (18%) who received 2 IVIg infusions had pain reduction of at least 2 points compared with their baseline score. Two patients in the blinded phase (1 in the placebo and 1 in the IVIg group) and 4 in the open IVIg phase had serious events. Results do not apply to patients who have had CRPS for less than 1 year or more than 5 years and do not extend to full-dose treatment (for example, 2 g/kg). The study was inadequately powered to detect subgroup effects. Low-dose immunoglobulin treatment for 6 weeks was not effective in relieving pain in patients with moderate to severe CRPS of 1 to 5 years' duration. Medical Research Council/National Institute for Health Research Efficacy and Mechanism Evaluation Program, Pain Relief Foundation, and Biotest United Kingdom.

12 September 2024 in The Journal of Pain
Verified
Journal Article
Open access
ATArnas Tamasauskas
Arnas Tamasauskas
BSBarbara Silva-Passadouro
Barbara Silva-Passadouro
NFNicholas Fallon
Nicholas Fallon
BFBernhard Frank
Bernhard Frank
SLSvajune Laurinaviciute
Svajune Laurinaviciute
AMAndrew G. Marshall
Andrew G. Marshall
Central post stroke pain (CPSP) is a neuropathic pain condition prevalent in 8% to 35% of stroke patients. This systematic review and meta-analysis aimed to provide insight in the effectiveness of available pharmacological, physical, psychological, and neuromodulation intervention in reducing pain in CPSP patients (PROSPERO Registration: CRD42022371835). Secondary outcomes included mood, sleep, global impression of change, and physical responses. Data extraction included participant demographics, stroke aetiology, pain characteristics, pain reduction scores, and secondary outcome metrics. Forty two original studies were included with a total of 1451 participants. No studies providing psychological therapy to CPSP patients were identified. Twelve studies met requirements for a random-effects meta-analyses that found: pharmacological therapy to have a small effect on mean pain score (SMD = -0.36, 96.0% Confidence Interval [-0.68, -0.03], physical interventions did not show a significant effect (SMD = -0.55, [-1.28, 0.18]), and neuromodulation treatments had a moderate effect (SMD -0.64, [-1.08, -0.19]). Fourteen studies were included in proportional meta-analysis with pharmacological studies having a moderate effect (58.3% mean pain reduction, [-36.51, -80.15]), and neuromodulation studies a small effect (31.1% mean pain reduction, [-43.45, -18.76]). Sixteen studies were included in the narrative review, findings from which largely supported meta-analyses results. Duloxetine, Amitriptyline and repetitive Transcranial Magnetic Stimulation (rTMS) had the most robust evidence for their effectiveness in alleviating CPSP induced pain. Further multi-centre placebo-controlled research is needed to ascertain the effectiveness of physical therapies, such as acupuncture and virtual reality, and invasive and non-invasive neuromodulation treatments. PERSPECTIVE: This article presents a top-down and bottom-up overview of evidence for the effectiveness of different pharmacological, physical, and neuromodulation treatments of CPSP. This review could provide clinicians with a comprehensive understanding of the effectiveness and tolerability of different treatment types.

1 November 2017 in Efficacy and Mechanism Evaluation
Verified
Journal Article
Closed access
AGAndreas Goebel
Andreas Goebel
JBJatinder Bisla
Jatinder Bisla
RCRoy Carganillo
Roy Carganillo
CCClaire Cole
Claire Cole
BFBernhard Frank
Bernhard Frank
GAGareth Ambler
Gareth Ambler
Background: Complex regional pain syndrome (CRPS) is a rare, severe post-traumatic pain condition affecting distal limbs. Patients who do not spontaneously improve in 12 months are classed as having ‘long-standing CRPS’ and often cannot be effectively treated, leading to a poor prognosis. CRPS is associated with functional autoantibodies. Two small trials, including a randomised controlled trial, have suggested that low-dose intravenous immunoglobulin (IVIg) may be an effective treatment for some patients. Objective: We hypothesised that low-dose IVIg is effective for reducing pain in long-standing CRPS. Methods: A randomised, double blinded placebo-controlled multicentre trial in seven UK pain management centres. Patients were eligible if they had moderate or severe long-standing CRPS that they had experienced for up to 5 years. Participants were randomly allocated to receive 0.5 g/kg IVIg, the active intervention, or visually indistinguishable 0.1% albumin in saline placebo. Randomisation was initiated by study sites via an independent online randomisation system and was 1 : 1 with varying block sizes, stratified by study centre. Participants, investigators and assessors were blinded to group assignment. The study drug/placebo was infused intravenously at the study centres on day 1 and day 23 after randomisation. The primary outcome was the 24-hour average pain intensity between day 6 and day 42, on an 11-point (0–10) numeric rating scale, compared between the groups. Outcomes were analysed using a mixed-effects regression model that used 37 measurements of pain intensity (the primary outcome) per participant. All patients who received an infusion and provided any outcome were included in the intention-to-treat analysis. Results: A total of 111 patients were recruited and assigned between 27 August 2013 and 28 October 2015. Three patients were excluded because they had been inappropriately randomised, five patients were withdrawn from the primary analysis because they provided no outcomes and 103 patients were analysed for the primary outcome. The average pain score in the IVIg group was 0.27 units (95% confidence interval –0.24 to 0.80 units) higher than in the placebo group. Therefore, there is no significant evidence of a treatment effect at the 5% level and there was no significant difference between groups. Six serious adverse events but no suspected unexpected serious adverse reactions were reported during the blinded and open-label phase. Conclusion and future work: Low-dose immunoglobulin was not effective in relieving pain in patients with moderate to severe CRPS of 1–5 years’ duration. Better drug treatments for long-standing CRPS are urgently required. Trial registration: Current Controlled Trials ISRCTN42179756. Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research partnership. Additional funding was obtained by the Pain Relief Foundation. Biotest UK Ltd provided the active study medication at no cost.

1 January 1991 in DMW - Deutsche Medizinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
BFB. Frank
B. Frank
FDF. Dörr
F. Dörr
GPG. Penkert
G. Penkert
EVE. Vogel
E. Vogel
GTG. Tidow
G. Tidow
Bei einem 26jährigen Patienten, der seit 11 Jahren an Morbus Crohn litt, entwickelte sich unter heftigen Schmerzen und Fieber bis 39°C innerhalb weniger Tage eine progrediente Kaudasymptomatik (schlaffe Paraparese, Sensibilitätsstörungen). Unter dem Verdacht auf einen Bandscheibenvorfall wurde eine spinale Computertomographie durchgeführt. Sie ergab intraspinales Weichteilgewebe sowie Gaseinschlüsse im Spinalkanal (L2-S3) und in der paravertebralen Muskulatur. Daraufhin wurde ein akuter epiduraler Abszeß diagnostiziert und eine Laminektomie vorgenommen (Höhe L4-S2). Intraspinal war schwartig verdicktes, bläulich verfärbtes Fettgewebe sichtbar; zwischen Duraschlauch und sakralen Wurzeln quoll rahmiger Eiter hervor. Der Wirbelkanal wurde mit einer epidural liegenden Saug-Spüldrainage versorgt. Ein postoperativer Kolon-Kontrasteinlauf ergab einen Fistelgang Richtung Kreuzbein. Der postoperative Verlauf wurde durch ein schweres Atemnot-Syndrom kompliziert, an dem der Patient 18 Tage nach der stationären Aufnahme starb. - Ein epiduraler Abszeß als Komplikation eines M. Crohn ist eine Rarität. Wegen der schlechten Prognose sollte bei jedem Patienten, bei dem sich Rückenschmerzen, Fieber oder sogar spinale Symptome einstellen, eine rasche Diagnostik mit Kernspin- oder Computertomographie veranlaßt werden. Progressive symptoms of caudal compression (flaccid paraparesis, sensory disorders), accompanied by severe pain and fever, developed over a few days in a 26-year-old man with Crohn's disease for 11 years. Spinal computed tomography, performed under the diagnosis of herniated disc, revealed intraspinal soft tissue, as well as gas in the spinal canal (L2-S3) and the paravertebral muscles. This led to the diagnosis of acute epidural abscess and a laminectomy was performed (at L4-S2). Intraspinally there was thickened, bluish fatty tissue; thick pus exuded between dura and the sacral roots. Suction-irrigation of the spinal canal was undertaken via an epidural drain. Postoperative contrast infusion into the colon demonstrated a fistula directed towards the sacrum. The postoperative course was complicated by severe respiratory impairment of which the patient died. - Epidural abscess is a rare complication of Crohn's disease. Because of its poor prognosis early diagnosis with magnetic resonance imaging or computed tomography should be undertaken in every patient with Crohn's disease who has back pain, fever or, particularly, symptoms of spinal compression.

10 September 2013 in Rheumatology
Verified
Journal Article
Open access
PDF file
AGAndreas Goebel
Andreas Goebel
SMSiraj Misbah
Siraj Misbah
KMKate MacIver
Kate MacIver
LHLouise Haynes
Louise Haynes
JBJanet Burton
Janet Burton
HPHelen Poole
Helen Poole
Sir, Complex regional pain syndrome (CRPS) is a post-traumatic limb pain associated with limb-confined sensory, autonomic, motor, skin and bone changes. Its causes are unknown, although recent studies have suggested an autoimmune contribution [1]. We previously reported success of repeated, pain-contingent, low-dose i.v. immunoglobulin treatments in reducing pain in one patient with severe intractable CRPS [2] and in a small, randomized controlled trial (RCT) we found that a single dose of IVIG reduced pain in patients with 6–30 months CRPS duration [3], but the duration of these effects was variable. To support the development of larger trials we investigated the potential long-term efficacy and cost-effectiveness of immunoglobulin treatment.